EXTERNAL QUALITY ASSESSMENT FOR HAEMOGLOBIN A 2

Similar documents
Haemoglobinopathies case studies 11 th Annual Sickle Cell and Thalassaemia Conference October 2017

Evaluation of UK NEQAS (H) Hb A 2 and related performance data

Perspective on performance: The Haemoglobinopathies. Barbara Wild

HEMOGLOBIN ELECTROPHORESIS DR ARASH ALGHASI SHAFA HOSPITAL-AHWAZ

HbF<2% 95-98% H b A %

Some Observations on Haemoglobin A 2

Screening for haemoglobinopathies in pregnancy

National Haemoglobinopathy Reference Laboratory. Information for Users

Pitfalls in the premarital testing for thalassaemia

Report of Beta Thalassemia in Newar Ethnicity

Dr Banu Kaya Consultant Haematologist Barts Health NHS Trust Royal London Hospital, London, UK SICKLE CELL AND THALASSAEMIA OVERVIEW

Joanne Mallon, Nora O Neill, Dr D Hull Antenatal midwife coordinator, Consultant Haematologist

HAEMATOLOGY CASE STUDIES SICKLE CELL SS

Unraveling Hemoglobinopathies with Capillary Electrophoresis

The pros and cons of the fourth revision of thalassaemia screening programme in Iran

Sickle Cell Disorder Referral Guidelines for Newborn Bloodspot Screening Wales Screening for Sickle Cell Disorder in Wales started on 1 June 2013

Hemoglobinopathy and thalassemia detection

Anaemia in Pregnancy

HPLC profile of sickle cell disease in central India

BRITISH BIOMEDICAL BULLETIN

You are a haemoglobin Lepore carrier

Current Topics in Hemoglobinopathies

Thalassemias:general aspects and molecular pathology

Green Amber Red Assurance Level

Detection and quantitation of hemoglobin (Hb) fractions

6.1 Extended family screening

H aemoglobin A2 can be measured by several laboratory

In adults, the predominant Hb (HbA) molecule has four chains: two α and two β chains. In thalassemias, the synthesis of either the α or the β chains

Thalassaemia and Abnormal Haemoglobins in Pregnancy

The diagnosis of Hemoglobinopathies

Counselling and prenatal diagnosis. Antonis Kattamis, Greece

Information for adult haemoglobinopathy carriers

Thalassemias. Emanuela Veras, M.D. 01/08/2006

Journal of Medical Science & Technology

HEMOLYTIC ANEMIA DUE TO ABNORMAL HEMOGLOBIN SYNTHESIS

Detecting and Reporting Alpha Thalassemia In Newborns

BETA (β) THALASSAEMIA ALPHA (α) THALASSAEMIA SICKLE CELL DISORDERS

Detection Of Abnormal Haemoglobin Variants By HPLC Method

assay Introduction Conclusions: The D-100 TM system proved to be a robust and reliable method for HbA 1c

Beta thalassaemia traits in Nigerian patients with sickle cell anaemia

Which variant haemoglobins are relevant? Haemoglobinopathies in the Diagnostic Laboratory. Which thalassaemias are relevant? Variant haemoglobins

Diagnostic difficulties in prevention and control program for thalassemia in Thailand: atypical thalassemia carriers

Dr.Abdolreza Afrasiabi

High Prevalence of Sickle Haemoglobin in Mehra Caste of District Betul, Madhya Pradesh

Barbara De la Salle Director, UK NEQAS Haematology

Evidence Based HbA1c Accuracy. Sabrina Koetsier Medical Scientist RCPAQAP Chemical Pathology

Next Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters

Expression of Hemoglobin Variant Migration by Capillary Electrophoresis Relative to Hemoglobin A 2. Improves Precision

The Challenging Diagnosis of Treacherous Hemoglobinopathies

Type and frequency of hemoglobinopathies, diagnosed in the area of Karachi, in Pakistan

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

MOLECULAR BASIS OF THALASSEMIA IN SLOVENIA

The Thalassemias in Clinical Practice. Ashutosh Lal, MD Director Comprehensive Thalassemia Program UCSF Benioff Children s Hospital Oakland

Seroprevalence of Sickle Cell Anemia And Thalassemia in Suspected Case of Genetic Disorders in Tribal Predominant Population, Ranchi,India

siderably. This paper reports on the use of this system in a screening program for thalassemia. Materials and methods

Clinical, haematological, and genetic studies of type 2

Information for adult haemoglobinopathy carriers You are a haemoglobin C carrier Your test result shows: Hb AC

Information for adult haemoglobinopathy carriers

Orignal Article. Neeraja Pethe, Anil Munemane*, Suryakant Dongre ABSTRACT

JMSCR Vol 06 Issue 01 Page January 2018

Success of Iran beta thalassemia prevention program:

Introduction reduction in output alter the amino acid sequence combination

Information for adult haemoglobinopathy carriers You are a sickle cell carrier Your test result shows: haemoglobin S carrier (Hb AS)

Antenatal Detection of Hemoglobinopathies using Red Blood Cells Indices for Screening

Information for adult haemoglobinopathy carriers

Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme

Information for fathers invited for a screening test for sickle cell disease and thalassaemia major

Potential of the Sebia Capillarys neonat fast automated system for neonatal screening of sickle cell disease

Gamma gene expression in haemoglobin disorders

Haemoglobin Lepore in a Malay family: a case report

Comparison of Sebia Capillarys Capillary Electrophoresis With the Primus High-Pressure Liquid Chromatography in the Evaluation of Hemoglobinopathies

KJLM. Comparison of Capillary Electrophoresis with Cellulose Acetate Electrophoresis for the Screening of Hemoglobinopathies INTRODUCTION

Cover Page. The handle holds various files of this Leiden University dissertation.

Genetic Modifiers of Sickle Cell Disease Severity. Kunle Adekile, MD, PhD Professor Department of Pediatrics Kuwait University

Studies on Beta Thalassemia and other Hemoglobinopathies in Metropolitan City of Chennai, Tamil Nadu, India

The Beats of Natural Sciences Issue 3-4 (September-December) Vol. 3 (2016)

Detection of Hemaglobinopathies in Anemic Children by HPLC method A Hospital Based Study

Quiz. What percentage of the world s population is a carrier of a hemoglobinopathy? Hemoglobinopathies in Pregnancy 1-2% 5-7% 8-12% 10-15%

FIT Laboratory update

Genetics of Thalassemia

Haemoglobinopathy Case Studies. Dr Jill Finlayson Department of Haematology Pathwest Laboratory Medicine

Prof Sanath P Lamabadusuriya

by Capillary Electrophoresis for Diagnosing β-thalassemia/ HbE Disease in Patients With Low HbF

Retraction Retracted: Detection of Abnormal Hemoglobin Variants by HPLC Method: Common Problems with Suggested Solutions

Newborn bloodspot results: predictive value of screen positive test for thalassaemia major

The influence of sickle cell and beta thalassaemia traits on type 2 diabetes mellitus

Thalassemia Maria Luz Uy del Rosario, M.D.

An overview of Thalassaemias and Complications

4 Fahed Al Karmi Sufian Alhafez Dr nayef karadsheh

Screening for Intermediate and Severe Forms of Thalassaemia in Discarded Red Blood Cells: Optimization and Feasibility

Your blood test results show you may be a carrier of alpha thalassaemia

Spectrum of hemoglobinopathies by high performance liquid chromatography with special reference to role of HbA2 levels at tertiary care centre

Haemoglobin BY: MUHAMMAD RADWAN WISSAM MUHAMMAD

State of the Art of HbA1c Measurement

Comprehensive Hemoglobin Analysis HBA1/2 (

Alpha_Zero_Thalas_07:1 24/4/07 11:14 Page 1. Alpha Zero

Effect of Hemoglobin Eon Glycosylated Hemoglobin Determinations Using Different Commercial Kits

Aneurin Bevan University Health Board Sickle Cell Anaemia and Haemoglobinopathy Screening and Management in Pregnancy Guidelines

INTERNAL QUALITY CONTROL ( Q I C) QC)

Research Article Pattern of β-thalassemia and Other Haemoglobinopathies: A Cross-Sectional Study in Bangladesh

Transcription:

EXTERNAL QUALITY ASSESSMENT FOR HAEMOGLOBIN A 2 Dr Barbara abaawild

The importance of Hb A 2 measurement Accurate and reliable measurement of Hb A 2 is essential for the diagnosis of beta thalassaemia trait Small difference (if any) between normal & abnormal levels Antenatal women should be screened for beta thalassaemia trait Carriers: recommend partner testing prediction of genetic risk Failure to detect condition may result in newborn with a medically significant condition

UKNEQAS: UK National External Quality Assessment Scheme All laboratories undertaking antenatal screening in England must participate in EQA scheme Required by: Accreditation ti bodies : National Screening Programme UKNEQAS Abnormal Haemoglobins Scheme issues 6 surveys per year, 3 samples per survey Specimens are accompanied by information on FBC, age, gender, ethnic group and clinical condition

UKNEQAS: UK National External Quality Assessment Scheme Participants are required to give analytical results and an interpretation With increase in technologies: Results of Hb A 2 measurement related to methodology used Identified differences in values obtained from different technologies and/or kits

National Sickle & Thalassaemia Screening Programme Established to provide a linked screening programme for antenatal women and newborn Universal screening Established laboratory standards Standardised reporting formats Standardised methodology (newborn) Decision algorithm (antenatal)

NSC&TSP: High Prevalence Screening FBC and HPLC Hb Variant HbS, HbC, HbD, HbE, Hb O Arab Hb Lepore Test partner Other variant refer to Consultant Haematologist* No variant MCH<27 MCH >= 27 HbA2 >= 3.5 beta thal trait HbA2 < 3.5 HbF > 5% HbA2 > 4.0 orhbf > 5% HbA2 =< 4.0 HbF =< 5% Test partner MCH < 25 MCH >= 25 Test partner refer to Consultant Haematologist* No further action Consider ethnic group Iron deficiency alpha thal High risk of alpha zero thalassaemia** low risk of alpha zero thalassaemia** No further action*** Test partner No further action

Review of Hb A 2 Data 2006-2008 2008 Review historic data for Hb A 2 Trends in Hb A 2 quantitation Methodology changes Differences in interpretation Develop and evaluate more sensitive indicators for monitoring performance Gather more information to evaluate the 3.5% cut-off for beta thalassaemia carrier status

Methodology 2000-20082008 Methodology for Hb A 2 measurement: Changes in methods used (e.g. column chromatography, electrophoresis, HPLC) Changes in analysers used (where HPLC analyser group is given) Note: only UK data will be presented in this talk

UK Hb A 2 analysis methods (2000-2008)

Change in CV for Hb A 2 measurement 2000-2008 0.2 0.18 0.16 0.14 0.12 01 0.1 0.08 0.06 0.04 0.02 0 0001AH1 0002AH3 0004AH3 0102AH1 0104AH1 0201AH1 0203AH1 0204AH2 0302AH1 0304AH1 0402AH2 0403AH3 0501AH3 0503AH2 0504AH2 CV 0601AH3 0602AH4 0603AH4 0702AH1 0703AH1 0703AH4 0801AH2 0802AH3 0803AH3 Survey number

Distribution ib i Curves Plotting the median Hb A 2 of the data set ± 3SDs Plotted all methods data and the data of the six largest method/analyser groups for all surveys from 2006 to mid- 2008 to look for trends Later analysed the results of borderline Hb A 2 sample 0902AH1 (all methods trimmed mean = 37%) 3.7%)

Normal sample:hb HbA2 26% 2.6%

B Beta thal h l traiti sample: l Hb A2 4.8% 4 8%

Borderline sample: Hb A 2 3.7% 3 Proba ability functio on mass 2.5 2 1.5 1 0.5 0 2 25 2.5 3 35 3.5 4 45 4.5 5 Hb A2 value

Hb A 2 Assessment Hb A 2 assessment codes: - low, normal, high or uncertain Results consensus if >85% of participants gave that answer outwith consensus groups since 2006: - Outwith consensus Hb A 2 result - Transcription or assessment error - Varying normal ranges between participants

Hb A 2 Assessment 5.1% 26.6%% 36.1% Outwith consensus result Varying normal range Transcription/ assessment error Combination of reasons 36.7%

Hb A 2 Reference Ranges

Beta thal trait specimens 2006-2008 No evidence of beta thalassaemia trait 30 participants

0604AH4: 0902AH1: 165 UK laboratories All methods trimmed mean = 3.7% Hb A 2 3.5% or greater: 16 did not give an interpretation of beta thalassaemia carrier 34 did not categorise the Hb A 2 as high 33 gave an Hb A 2 value of 3.4% or less 172 UK laboratories All methods trimmed mean = 3.7% Hb A 2 3.5% or greater: 22 did not give an interpretation of beta thalassaemia carrier 37 did not categorise the Hb A 2 as high 26 gave an Hb A 2 value of 3.4% or less

UKNEQAS

Current developments Instrument t calibration-use of calibrant(s) Development of new Hb A 2 reference material Target value for performance scoring: Target value for performance scoring: all methods mean method-specific mean current target submethod-specific mean

Causes of f raised dhba 2 Beta thalassaemia trait Unstable beta globin variants HIV infection - usually treatment related Metabolic disorder Oth h l bi thi Other haemoglobinopathies Artefact, eg HbS adducts

Sickle cell trait Normal FBC Hb S% : 35-45 Hb A 2 may be raised Consider omitting A 2 value from report

Hb Sβ β + thalassaemia

δ chain variant Consider total Hb A 2 and review red cell indices Note: also check for carry-over

Silent β thalassaemia trait (normal MCV, MCH, and Hb A2 %) Almost silent β thalassaemia trait (reduced MCV, MCH, normal Hb A2 %) Indices typical of thalassaemia trait but Hb A2 % normal

Risk assessment The following conditions will be missed: Silent or near silent beta thalassaemia carrier Possible beta thalassaemia carrier obscured by severe iron deficiency Alpha zero thalassaemia occurring outside of the defined at-risk family origins Dominant haemoglobinopathies where the woman has no haemoglobinopathy Any significant variant not detected by HPLC

Borderline / normal Hb A 2 value and beta thalassaemia Normal Hb A 2 thalassaemia Borderline / normal Hb A 2 (3.2% 3.8%) Reduced red cell indices eg CAP+1 A>C Silent beta thalassaemia Normal Hb A 2 (2.5% 3.8%) Normal Hb A 2 (2.5% 3.8%) Normal red cell indices eg -101C>T

29 Measurement of Hb A 2 ICSH recommendations ISLH Oct 2011 Previous ICSH recommendations written in 1978 Hb A 2 is measured as a percentage of haemoglobin present relative to any other haemoglobin present not an absolute value Therefore analytically important to measure the A 2 and any other fractions present separation, resolution and integration crucial In the presence of an Hb A 2 variant, it is the total of the normal and abnormal Hb A 2 which is significant 2 g

30 ICSH recommendations ISLH Oct 2011 Fraction separation by HPLC Electrophoresis with elution or microcolumn chromatography Quantification by spectrophotometry at 415nm Capillary Zone Electrophoresis Capillary Isoelectric Focusing DNA analysis is required for the characterization of beta thalassaemia mutations

31 ICSH recommendations ISLH Oct 2011 Measurement of the Hb A 2 alone cannot absolutely confirm or exclude the carrier state as the there may be little difference between A 2 in normals and some beta thalassaemia carriers Precision levels should be +/- 0.1% of the final answer (SD 0.05%) 05%) Common beta thalassaemia trait Hb A 2 = 4.0-6.0% Beta thalassaemia trait overall usually Hb A 2 = 3.5-7.0% Normal subjects usually Hb A 2 = 22-3 2.2 3.3% 3%

Considerations i Use of different normal ranges variation even within same instrument group Use of a universal cut-off Instrument bias impact on borderline values Examination of chromatograms Varying causes of a raised Hb A 2

Ak Acknowledgements ld Hannah Batterbee Royal Hallamshire Hospital Barbara Dela Salle UKNEQAS(H) Dr John Old National Haemoglobinopathy Reference Laboratory, Oxford